EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial

Rana F Hilal iD, Nourhan Osama, Samar El-Tahlawi, Amira Elbendary iD, Zeinab A Nour iD, Nanis Ragab iD

International Journal of Dermatology · 2026

DOI: 10.1111/ijd.70548 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Rana F Hilal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kasr Al Ainy Teaching Hospital, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Triamcinolone Acetonide, Bevacizumab, Keloid, Angiogenesis Inhibitors. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Keloids are an abnormal fibroproliferative disorder that often causes pruritus, pain, and hyperpigmentation, thereby significantly impacting quality of life. Vascular endothelial growth factor (VEGF) is upregulated in scars and, therefore, can be a potential target for their treatment.

Objectives

Our aim was to evaluate the efficacy and safety of intralesional triamcinolone acetonide (TAC) versus intralesional bevacizumab injection in the treatment of post‐traumatic keloids.

Methods

This randomized clinical trial was conducted on 28 adult patients with post‐traumatic keloids. Patients were randomized into two groups; one group received intralesional triamcinolone acetonide, and the other received intralesional bevacizumab. Injections were done monthly. Patients received a total of three sessions. Therapeutic efficacy was defined in terms of the modified Vancouver Scar Scale (mVSS), erythema index by spectrophotometry, histopathological evaluation, and biochemical assessment of VEGF, collagen type I, and collagen type III levels.

Results

A statistically significant difference in mVSS was observed between the triamcinolone acetonide and bevacizumab groups, favoring the TAC group. The TAC group showed a significant decrease in VEGF level and an increase in collagen type III after treatment. The bevacizumab group showed significant improvement in the spacing between collagen fibers after treatment. The patient satisfaction score and the physician global assessment revealed superior outcomes regarding intralesional triamcinolone acetonide.

Conclusion

Despite the superior results observed with triamcinolone, bevacizumab warrants further investigation to determine whether it can be used for early and vascular keloids or as an adjuvant to optimize results. Trial Registration: ClinicalTrials.gov identifier: NCT07014280. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triamcinolone AcetonideBevacizumabKeloidAngiogenesis InhibitorsGlucocorticoidsHumansAdultInjections, IntralesionalFemaleMaleVascular Endothelial Growth Factor AYoung AdultTreatment OutcomeMiddle AgedCollagen Type IIICollagen Type IAdolescent

Stichwörter der Autor:innen

bevacizumabintralesionalkeloidstriamcinolone acetonidevascular endothelial growth factor (VEGF)

Substanzen

Triamcinolone AcetonideBevacizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor AGlucocorticoidsCollagen Type IIICollagen Type I

Autor:innen und Institutionen

  • Department of Dermatology, Kasr Al Ainy Teaching Hospital, Cairo University, Cairo, Egypt.
  • Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt.

ORCID-Profile: Rana F Hilal, Amira Elbendary, Zeinab A Nour, Nanis Ragab

Zitieren

APA

Hilal, R. F., Osama, N., El-Tahlawi, S., Elbendary, A., Nour, Z. A., & Ragab, N. (2026). Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial. International Journal of Dermatology. https://doi.org/10.1111/ijd.70548

Vancouver

Hilal RF, Osama N, El-Tahlawi S, Elbendary A, Nour ZA, Ragab N. Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial. International Journal of Dermatology. 2026. doi:10.1111/ijd.70548

BibTeX
@article{Hilal2026,
  author = {Hilal, Rana F and Osama, Nourhan and El-Tahlawi, Samar and Elbendary, Amira and Nour, Zeinab A and Ragab, Nanis},
  title = {Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70548}
}
Kostenlos starten →